Therapeutic options in MDS

Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic malignancies characterized by peripheral blood cytopenias, due to ineffective erythropoiesis and a risk for progression to acute myeloid leukemia (AML). Progress in this field aims to decrease the transfusion burden, delay progression to AML, improve the quality-of-life of patients and extend survival.

(BELG J HEMATOL 2016; 7(1): 20–4)